Antibody-drug conjugates in prostate cancer: current landscape and future directions
Therapeutic Advances in Medical Oncology · 2026-03 · 18
DOI: 10.1177/17588359261424672 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 13.03.2026. Verfasst von Zeynep Irem Ozay und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Antibody-drug conjugates (ADCs) have emerged as a promising therapeutic option, combining the specificity of monoclonal antibodies with the potency of cytotoxic payloads. While initially developed for hematologic and select solid malignancies, advances in antigen discovery, linker chemistry, and payload design have expanded their application to metastatic castration-resistant prostate cancer, where treatment options remain limited. Prostate-specific membrane antigen (PSMA), STEAP-1, TROP-2, CD46, Nectin-4, tissue factor, B7-H3, and DLL3 have emerged as clinically relevant targets, with multiple ADCs evaluated in early and late-phase trials. Although early-generation drugs were hindered by modest efficacy and significant toxicity due to linker instability and off-target effects, some novel ADCs have shown improved tolerability and encouraging antitumor activity. Ongoing studies are exploring rational combinations with hormonal, other targeted, and immune-based therapies to enhance efficacy, overcome resistance, and expand the role of ADCs in advanced prostate cancer. Herein, we provide a comprehensive overview of the clinical development of ADCs in advanced prostate cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.
- Division of Hematology and Oncology, Department of Internal Medicine, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX.
- Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope Drive Suite 5510, Salt Lake City, UT 84112, USA.
Zitieren
APA
Ozay, Z. I., Hage Chehade, C., Gebrael, G., Ostrowski, M., Sayegh, N., Swami, U., & Agarwal, N. (2026). Antibody-drug conjugates in prostate cancer: current landscape and future directions. Therapeutic Advances in Medical Oncology, 18. https://doi.org/10.1177/17588359261424672
Vancouver
Ozay ZI, Hage Chehade C, Gebrael G, Ostrowski M, Sayegh N, Swami U, et al. Antibody-drug conjugates in prostate cancer: current landscape and future directions. Therapeutic Advances in Medical Oncology. 2026;18. doi:10.1177/17588359261424672
BibTeX
@article{Ozay2026,
author = {Ozay, Zeynep Irem and Hage Chehade, Chadi and Gebrael, Georges and Ostrowski, Micah and Sayegh, Nicolas and Swami, Umang and Agarwal, Neeraj},
title = {Antibody-drug conjugates in prostate cancer: current landscape and future directions},
journal = {Therapeutic Advances in Medical Oncology},
year = {2026},
volume = {18},
doi = {10.1177/17588359261424672}
}
EUVIMED